EBNA1 may prolong G(2)/M phase and sensitize HER2/neu-overexpressing ovarian cancer cells to both topoisomerase II-targeting and paclitaxel drugs

CMUR > College of Medicine > Graduate Institute of Clinical Medical Science > Journal articles > Item 310903500/7105

Please use this identifier to cite or link to this item: http://ir.cmu.edu.tw/ir/handle/310903500/7105

Title:	EBNA1 may prolong G(2)/M phase and sensitize HER2/neu-overexpressing ovarian cancer cells to both topoisomerase II-targeting and paclitaxel drugs
Authors:	(Chuang TC);(Lee YJ);(Liu JY);(Lin YS);(Li JW);(Wang V);(Law SL);高銘欽(Ming-Ching Kao)*
Contributors:	醫學院臨床醫學研究所
Keywords:	HER2/neu;EBNA1;Tumorigenicity;Ovarian cancer
Date:	2003-08
Issue Date:	2009-08-26 16:12:45 (UTC+8)
Abstract:	We have shown previously that the Epstein–Barr virus nuclear antigen-1 (EBNA1) can act as a transforming suppressor in the HER2/neu-overexpressing ovarian cancer cells. In the present study, by using flow cytometric analysis, we demonstrate that EBNA1 could prolong G2/M phase and sensitize to Taxol-induced apoptosis in the EBNA1-expressing ovarian cancer cell stable transfectants. In addition, EBNA1 could also significantly increase topoisomerase IIα protein expression, indicating that the up-regulation of topoisomerase IIα may be one of the mechanisms by which EBNA1 enhances the sensitivity of ovarian cancer cells to topoisomerase II-targeting anticancer drugs, such as VP-16 and Adriamycin. These data suggest that EBNA1 not only prolongs cell cycle at G2/M phase and up-regulates topoisomerase IIα expression in HER2/neu-overexpressing ovarian cancer cells, but also increases cellular apoptosis through sensitization of cancer cells to topoisomerase II-directing anticancer drugs.
Relation:	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 307(3)653~659
Appears in Collections:	[Graduate Institute of Clinical Medical Science] Journal articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	360	View/Open

Loading...